Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
A phase 1/2 trial of Sunvozertinib in non-small-cell lung cancer and small-cell lung cancer, run by Dizal Pharmaceuticals, active and no longer recruiting.
Overview
Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) is a phase 1/2 interventional study registered as NCT03974022 by Dizal Pharmaceuticals, with 315 participants enrolled, started 2019-07-09 and due to reach its primary completion in 2024-07-29. Interventions recorded: Sunvozertinib. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialStudy of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Shares Sunvozertinib, Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)
Shares Sunvozertinib, Dizal Pharmaceutical, Non-small-cell lung cancer.
- TrialA Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Ins
Shares Sunvozertinib, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialDZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Shares Dizal Pharmaceutical, Small-cell lung cancer, Non-small-cell lung cancer.
- TermEGFR exon 20 insertion
Shares Sunvozertinib, Non-small-cell lung cancer.